Sexually Transmitted Infections (STIs) are a significant health challenge facing the United States. The CDC estimates that nearly 20 million new sexually transmitted infections occur every year in this country, half among young people ages 15–24, accounting for almost $16 billion in health care costs. Each of these infections is a potential threat to an individual’s immediate and long-term health and well-being. In addition to increasing a person’s risk for acquiring and transmitting HIV infection, STIs can lead to severe reproductive health complications, such as infertility and ectopic pregnancy.
The worldwide market for Sexually Transmitted Infection testing is in excess of $1B and includes testing for Gonorrhea (NG), Chlamydia (CT), Trichomonas, Herpes (HSV), Human Papilloma Virus (HPV) and testing for vaginitis and vaginosis. This market is fragmented between the various tests that are often run on different platforms from multiple vendors.
Applied BioCode is currently developing a multiplex molecular panel for detection of common infectious agents causing STIs. The BioCode STI Panel* combines CT/NG, Trichomonas, HSV-1 and HSV-2, and Mycoplasma genitalium. This unique and broad spectrum test of infectious agents will complement HPV and possible HIV screening, particularly for women’s health management. The Applied BioCode STI Panel* will be available on our new BioCode MDX 3000 System which combines nucleic acid amplification, hybridization, signal generation and detection steps for this assay. The automation of these steps into a single system will decrease costs, hands on time, and minimize potential contamination risk.
The Applied BioCode STI panel is a multiplexed nucleic acid test intended for the simultaneous qualitative detection and identification of:
|Applied BioCode STI Panel*|
• Neisseria gonorrhoeae (GC)
• Mycoplasma genetailium
* The product is currently Under Development.
For more information about these products or to discuss a potential study, please contact us via: